122 related articles for article (PubMed ID: 23628646)
21. Production of bulk chemicals via novel metabolic pathways in microorganisms.
Shin JH; Kim HU; Kim DI; Lee SY
Biotechnol Adv; 2013 Nov; 31(6):925-35. PubMed ID: 23280013
[TBL] [Abstract][Full Text] [Related]
22. Identification and immunological characterization of conserved Mycoplasma hyopneumoniae lipoproteins Mhp378 and Mhp651.
Meens J; Selke M; Gerlach GF
Vet Microbiol; 2006 Aug; 116(1-3):85-95. PubMed ID: 16650945
[TBL] [Abstract][Full Text] [Related]
23. Differential genome analyses of metabolic enzymes in Pseudomonas aeruginosa for drug target identification.
Perumal D; Lim CS; Sakharkar KR; Sakharkar MK
In Silico Biol; 2007; 7(4-5):453-65. PubMed ID: 18391237
[TBL] [Abstract][Full Text] [Related]
24. Proteomic analysis of the interactions between Mycoplasma hyopneumoniae and porcine tracheal ciliated cells.
Li YZ; Ho YP; Chen ST; Shiuan D
Appl Biochem Biotechnol; 2010 Apr; 160(8):2248-55. PubMed ID: 19672722
[TBL] [Abstract][Full Text] [Related]
25. Application of the Subtractive Genomics and Molecular Docking Analysis for the Identification of Novel Putative Drug Targets against
Hossain T; Kamruzzaman M; Choudhury TZ; Mahmood HN; Nabi AHMN; Hosen MI
Biomed Res Int; 2017; 2017():3783714. PubMed ID: 28904956
[TBL] [Abstract][Full Text] [Related]
26. Protein interaction network analysis--approach for potential drug target identification in Mycobacterium tuberculosis.
Kushwaha SK; Shakya M
J Theor Biol; 2010 Jan; 262(2):284-94. PubMed ID: 19833135
[TBL] [Abstract][Full Text] [Related]
27. [Immunogenicity of attenuated Salmonella choleraesuis vaccine strain expressing immunogenic genes of Mycoplasma hyopneumoniae in mice].
Ma F; Zou H; He Q
Wei Sheng Wu Xue Bao; 2011 Sep; 51(9):1270-7. PubMed ID: 22126084
[TBL] [Abstract][Full Text] [Related]
28. Proteomic study of Mycoplasma suis using the gel-based shotgun strategy.
Yuan C; Yang X; Yang Z; Zhu N; Zheng S; Hou P; Gu X; Ye C; Yao C; Zhu J; Cui L; Hua X
Vet Microbiol; 2010 May; 142(3-4):303-8. PubMed ID: 19969430
[TBL] [Abstract][Full Text] [Related]
29. Immunisation of mice with Mycoplasma hyopneumoniae antigens P37, P42, P46 and P95 delivered as recombinant subunit or DNA vaccines.
Galli V; Simionatto S; Marchioro SB; Fisch A; Gomes CK; Conceição FR; Dellagostin OA
Vaccine; 2012 Dec; 31(1):135-40. PubMed ID: 23137841
[TBL] [Abstract][Full Text] [Related]
30. Mhp182 (P102) binds fibronectin and contributes to the recruitment of plasmin(ogen) to the Mycoplasma hyopneumoniae cell surface.
Seymour LM; Jenkins C; Deutscher AT; Raymond BB; Padula MP; Tacchi JL; Bogema DR; Eamens GJ; Woolley LK; Dixon NE; Walker MJ; Djordjevic SP
Cell Microbiol; 2012 Jan; 14(1):81-94. PubMed ID: 21951786
[TBL] [Abstract][Full Text] [Related]
31. Understanding alternative fluxes/effluxes through comparative metabolic pathway analysis of phylum actinobacteria using a simplified approach.
Verma M; Lal D; Saxena A; Anand S; Kaur J; Kaur J; Lal R
Gene; 2013 Dec; 531(2):306-17. PubMed ID: 24055419
[TBL] [Abstract][Full Text] [Related]
32. Metabolic modeling of energy balances in Mycoplasma hyopneumoniae shows that pyruvate addition increases growth rate.
Kamminga T; Slagman SJ; Bijlsma JJE; Martins Dos Santos VAP; Suarez-Diez M; Schaap PJ
Biotechnol Bioeng; 2017 Oct; 114(10):2339-2347. PubMed ID: 28600895
[TBL] [Abstract][Full Text] [Related]
33. Identification of immunogenic polypeptides from a Mycoplasma hyopneumoniae genome library by phage display.
Kügler J; Nieswandt S; Gerlach GF; Meens J; Schirrmann T; Hust M
Appl Microbiol Biotechnol; 2008 Sep; 80(3):447-58. PubMed ID: 18636254
[TBL] [Abstract][Full Text] [Related]
34. Potential use of a recombinant replication-defective adenovirus vector carrying the C-terminal portion of the P97 adhesin protein as a vaccine against Mycoplasma hyopneumoniae in swine.
Okamba FR; Arella M; Music N; Jia JJ; Gottschalk M; Gagnon CA
Vaccine; 2010 Jul; 28(30):4802-9. PubMed ID: 20472025
[TBL] [Abstract][Full Text] [Related]
35. Proteomic comparative analysis of pathogenic strain 232 and avirulent strain J of Mycoplasma hyopneumoniae.
Li YZ; Ho YP; Chen ST; Chiou TW; Li ZS; Shiuan D
Biochemistry (Mosc); 2009 Feb; 74(2):215-20. PubMed ID: 19267678
[TBL] [Abstract][Full Text] [Related]
36. Immune responses induced by replication-defective adenovirus expressing the C-terminal portion of the Mycoplasma hyopneumoniae P97 adhesin.
Okamba FR; Moreau E; Cheikh Saad Bouh K; Gagnon CA; Massie B; Arella M
Clin Vaccine Immunol; 2007 Jun; 14(6):767-74. PubMed ID: 17409219
[TBL] [Abstract][Full Text] [Related]
37. Comparative genomics analysis of Mycobacterium ulcerans for the identification of putative essential genes and therapeutic candidates.
Butt AM; Nasrullah I; Tahir S; Tong Y
PLoS One; 2012; 7(8):e43080. PubMed ID: 22912793
[TBL] [Abstract][Full Text] [Related]
38. Chemical and genomic evolution of enzyme-catalyzed reaction networks.
Kanehisa M
FEBS Lett; 2013 Sep; 587(17):2731-7. PubMed ID: 23816707
[TBL] [Abstract][Full Text] [Related]
39. P159 is a proteolytically processed, surface adhesin of Mycoplasma hyopneumoniae: defined domains of P159 bind heparin and promote adherence to eukaryote cells.
Burnett TA; Dinkla K; Rohde M; Chhatwal GS; Uphoff C; Srivastava M; Cordwell SJ; Geary S; Liao X; Minion FC; Walker MJ; Djordjevic SP
Mol Microbiol; 2006 May; 60(3):669-86. PubMed ID: 16629669
[TBL] [Abstract][Full Text] [Related]
40. Two domains within the Mycoplasma hyopneumoniae cilium adhesin bind heparin.
Jenkins C; Wilton JL; Minion FC; Falconer L; Walker MJ; Djordjevic SP
Infect Immun; 2006 Jan; 74(1):481-7. PubMed ID: 16369004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
